- Home
- BJDX vs GTBP Comparison
BJDX vs GTBP Comparison
Compare BJDX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJDX | GTBP |
|---|---|---|
| Founded | 2015 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BJDX | GTBP |
|---|---|---|
| Price | $1.21 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 78.6K | ★ 1.4M |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $55.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.13 | $0.54 |
| 52 Week High | $10.20 | $4.10 |
Technical Indicators
Market Signals| Indicator | BJDX | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 34.01 | 43.01 |
| Support Level | $1.24 | $0.58 |
| Resistance Level | $1.51 | $0.82 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.00 | 8.05 |
Price Performance
Historical ComparisonAbout BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.